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Use of angiotensin converting enzyme inhibitors is
associated with increased growth rate of
abdominal aortic aneurysms
Michael J. Sweeting,a Simon G. Thompson,a Louise C. Brown,b Roger M. Greenhalgh,b and
Janet T. Powell,b Cambridge and London, United Kingdom
Objectives: To evaluate whether either angiotensin converting enzyme (ACE) inhibitors or other classes of antihyperten-
sive drug attenuate or increase growth rates of small infrarenal abdominal aortic aneurysms.
Methods: Prospective cohort study of 1701 patients enrolled in the UK Small Aneurysm Trial or associated study at 93
hospitals between 1991 and 1995 and who had at least two ultrasound measurements of aneurysm diameter and baseline
drug prescription data recorded. Abdominal aortic aneurysm diameter was measured in the anterior-posterior plane using
ultrasound. The mean growth rate was estimated through a mixed-effects linear growth model.
Results:Mean aneurysm growth rate in 169 patients taking ACE inhibitors at baseline was 3.33 mm/y vs 2.77 mm/y in
the remaining 1532 patients, P  .009. The significance of this finding did not alter after adjustment for known
confounders. The prescription of any antihypertensive agent and other specific classes of antihypertensive drugs were not
found to be associated with aneurysm growth rate.
Conclusion: These results show that patients taking ACE inhibitors have faster aneurysm growth and are in conflict with the
observation from a large Canadian data-base that aneurysm patients taking ACE inhibitors are less likely to present with
aneurysm rupture. There is an urgent need for a randomized trial to assess whether ACE inhibitors are beneficial or harmful
to patients with aneurysms below the threshold size for surgical intervention. (J Vasc Surg 2010;52:1-4.)The effectiveness of national aneurysm screening
programs, including the UK National Abdominal aortic
aneurysm (AAA) Screening program,1 would be im-
proved if there was a simple drug treatment to slow or
arrest aneurysm growth. Such a treatment could limit the
number of small aneurysms reaching the diameter
threshold, when surgical intervention to exclude the
aneurysm is considered, and hence reduce the number of
operations required and the associated operative mor-
bidity and mortality. A number of studies have investi-
gated the influence of various medical therapies on an-
eurysm growth rate and there have been randomized
trials of beta-blockers and antibiotics. These have been
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doi:10.1016/j.jvs.2010.02.264summarized in a systematic review and meta-analysis
with little evidence to suggest any strong contenders for
reduction in growth rates apart from possibly statins and
other anti-inflammatory drugs.2 This meta-analysis in-
cluded very limited data on the effects of angiotensin
converting enzyme (ACE) inhibitors but a retrospective
case-control study using a large Canadian administrative
database showed that for patients admitted to hospital
with a diagnosis of abdominal aortic aneurysm, those
taking ACE inhibitors were less likely to present with
ruptured aneurysm.3 As a consequence, these authors
suggested that ACE inhibition might also be associated
with a reduction in aneurysm growth rates and that a
pilot trial was indicated. This is one of the important
pieces of evidence that has led the UK National Institute
for Health Research to commission a randomized trial to
assess whether ACE inhibitors significantly reduce aneu-
rysm growth rates.4
The retrospective review of the Canadian database for
aneurysm rupture spanned the time period 1992 to 2002.3
This time period overlapped with the recruitment of pa-
tients to the UK Small Aneurysm Trial and Study, 1991 to
1995, in which a large cohort of patients with small abdom-
inal aortic aneurysms were followed up for aneurysm
growth.5-7 Drug therapy at baseline had been recorded and
coded and this provided the opportunity to test the hypoth-
esis that the use of either ACE inhibitors, or other antihy-
1
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rysm growth rates.
METHODS
Data. Data were obtained from the UK Small Aneu-
rysm Trial and Study, details of which are published else-
where.5-7 Briefly, patients aged 60 to 76 years with an
asymptomatic infrarenal abdominal aortic aneurysm were
entered into the trial or study from 93 hospitals across the
UK between August 1991 and October 1995: ethical ap-
proval was obtained at each participating hospital. Individ-
uals with AAA diameter between 40 and 55 mm and who
were fit for surgery were eligible for recruitment into the
UK Small Aneurysm Trial, which randomized them to
either immediate surgery or surveillance. In addition, study
coordinators followed a further group of study patients
who were either not eligible or refused entry into the trial.
For inclusion in this analysis, patients were required to have
at least two AAA diameter measurements and have drug
prescription data recorded at baseline.
Aneurysm diameter in the anterior-posterior plane was
measured via ultrasound. Follow-up in the surveillance arm
and in the study was every 6 months for patients with
aneurysms less than 50mm in diameter and every 3 months
for larger diameters. In addition, repeated measurements
were also available from some patients in the surgery arm
prior to randomization. Repeatability of ultrasound mea-
surements between trial coordinators was assessed regularly
during the study and found to be satisfactory.5
At baseline, information was obtained on smoking
status, history of diabetes and hypertension, presence of
ischemic heart disease (IHD) coded as unlikely, possible, or
probable according to an electrocardiogram (ECG) and
ankle-brachial pressure index (ABPI). In addition, compre-
hensive information was also recorded about any drugs
currently being prescribed to the patient; dosage of drugs
was not recorded. The drug categories recorded included
statins, antiplatelet therapy, and antihypertensive drugs.
The following specific classes of antihypertensive agents
were coded: ACE inhibitors, calcium channel blockers,
beta-blockers as well as any antihypertensive agent (also
including diuretics, vasodilators such as hydralazine,
-adrenoreceptor blockers, and the three patients taking
angiotensin receptor blockers).
Statistical analysis. The primary outcome of the in-
vestigation was the effect of ACE inhibitors on aneurysm
growth rates. The analysis was performed according to a
statistical analysis plan agreed before any of the growth data
were inspected by ACE inhibitor or other drug use. A
mixed-effects linear growth model with AAA diameter as
the dependent variable was used to estimate the effects of
drug use on the rate of AAA growth and to allow for
repeated measurements within individuals. The statistical
analysis was performed using STATA version 11 (STATA
Corporation, College Station, Tex). The baseline AAA
diameter and the linear rate of growth were modelled as
bivariate normal random effects to allow for between-
patient variation in these characteristics. This type of anal-ysis accounts for any correlation between the baseline di-
ameter and the rate of growth.7-9 Patient characteristics
and drug categories were entered into the model as fixed
effects to assess any effects on baseline diameter and as
interaction terms with time to assess any effects on the
linear rate of growth.
Two levels of adjustment were made for potential con-
founders. The partially adjusted model included age at
baseline, sex, and baseline AAA diameter, and the fully
adjusted model also included smoking status, IHD, APBI,
diabetes, history of hypertension, and each of the other
drug categories. A Bonferroni correction for multiple test-
ing for six drug categories suggests judging statistical sig-
nificance at a level of .009 (if P  .05 is the level of testing
for one hypothesis). The analyses were conducted on cases
with complete baseline covariate information for the model
being considered.
Two additional sensitivity analyses were performed to
investigate whether results changed; first, missing data were
multiply imputated using chained equations10 to use infor-
mation from all individuals, and second, a quadratic growth
term was included in the model.
RESULTS
Seven hundred four (704) trial and 1039 study patients
had at least two recorded AAA diameter measurements. Of
these 1743 individuals, 1701 have drug prescription data
recorded providing a total of 3289 person-years of
follow-up (mean, 1.9 years) and 8979 AAA measurements
(mean, 5.3).
A summary of the characteristics of the 1701 patients
stratified by ACE inhibitor prescription is shown in Table I.
The mean baseline diameter was 43 mm (SD 7) and 78% of
the cohort was male. Over 90% were current smokers or
had smoked previously and a large proportion of patients
(43%) had a history of hypertension. About one-half of the
patients were taking antihypertensive medication at base-
line, 30%were on antiplatelet therapy, 25%were on calcium
channel blockers, 15% on -blockers, and 10% were on
ACE inhibitors, whereas very few individuals had been
prescribed statins. Those prescribed ACE inhibitors at
baseline had, on average, larger baseline aneurysm diame-
ters, a higher prevalence of ischemic heart disease, lower
ankle/brachial pressure index, were more likely to have a
history of hypertension and were also more likely to be on
statins or antiplatelet therapy at baseline.
The effects of drug prescription on AAA growth rates
are presented in Table II. The average growth rate in this
cohort was estimated as 2.83 mm/y (95% confidence in-
terval [CI], 2.71, 2.95). There was evidence of an associa-
tion between ACE inhibitor use and increased growth rates
(P .009), which persisted even after fully adjusting for
patient characteristics and the use of other drug categories
at baseline. Individuals on ACE inhibitors had on average a
0.63 mm/yr (SE 0.24, P  .009) increased rate of growth
compared with individuals not on ACE inhibitors (average
growth rates 3.37 and 2.74 mm/y, respectively). The
increased growth rate for those individuals taking ACE
s.
therap
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separately. There was little evidence that the prescription of
any other drugs were associated with aneurysm growth,
although the size of the treatment effect (0.90mm/y) for
the small number of patients taking statins hints at a pro-
tective effect.
The sensitivity analyses, assessing the inclusion of a
random quadratic term for AAA diameter or multiple im-
Table I. Summary of patient characteristics
Patient characteristics
Patient numbers availabl
for analysis
Age at baseline, years 1701
Baseline AAA diameter, mm 1701
Male gender 1701
Smoking status 1690
Never
Ex
Current
Ischemic heart disease from ECG 1607
Unlikely
Possible/probable
Ankle-brachial pressure index 1659
Diabetes 1681
History of hypertension 1682
Drug use at baseline
Any antihypertensives 1701
Calcium channel blockers 1701
Beta-blockers 1701
Statins 1701
Antiplatelet therapy 1701
n (%) presented for categorical variables, mean (SD) for continuous variable
a2 test for categorical variables, t test for continuous variables.
Table II. Estimated effect of baseline drug use on AAA g
Drug prescription at
baseline (number
taking drug)
Partially adjusted analysisa
Effect on rate of growth
No. patients  1701
No. observations  8979
Mean growth
rate for
patients
taking drug/
not taking
drug (mm/y)
Regression
coefficient for
difference
between groups
(mm/y)
Stand
erro
Any antihypertensives
(900) 2.81/2.84 0.03 0.1
ACE inhibitors (169) 3.33/2.77 0.56 0.2
Calcium channel
blockers (440) 2.76/2.85 0.09 0.1
Beta-blockers (255) 2.70/2.85 0.15 0.1
Statins (21) 2.07/2.84 0.76 0.5
Antiplatelet therapy
(501) 2.89/2.80 0.09 0.1
AAA, Abdominal aortic aneurysm; ABPI, ankle-brachial pressure index; AC
aAdjusted for baseline age, sex, and baseline AAA diameter.
bAdjusted for baseline age, sex, baseline AAA diameter, smoking status, IHD
inhibitors, calcium channel blockers, beta-blockers, statins, and antiplatelet
cObtained from aWald test: after application of the Bonferroni correction to allputation for patients with missing baseline covariates, didnot change the results substantially, and the effect of ACE
inhibitors remained significant throughout.
DISCUSSION
Surprisingly, our data indicate an association between
ACE inhibition and increased aneurysm growth rate. This
comes in spite of the mounting experimental evidence to
ACE inhibitor use
(n  169)
No ACE inhibitor use
(n  1532) P valuea
68.6 (4.0) 69.5 (4.5) .012
44.1 (7.4) 42.7 (6.8) .007
126 (74.6) 1201 (78.4) .253
.148
9 (5.3) 96 (6.3)
109 (64.5) 862 (56.7)
51 (30.2) 563 (37.0)
.001
60 (38.2) 816 (56.3)
97 (61.8) 634 (43.7)
0.86 (0.22) 0.93 (0.21) .001
12 (7.1) 63 (4.2) .080
142 (84.0) 586 (38.7) .001
169 (100.0) 731 (47.7) .001
52 (30.8) 388 (25.3) .125
23 (13.6) 232 (15.1) .596
6 (3.6) 15 (1.0) .004
64 (37.9) 437 (28.5) .011
rate
Fully adjusted analysisb
Effect on rate of growth
No. patients  1556
No. observations  8419
P
valuec
Mean growth
rate for
patients
taking drug/
not taking
drug (mm/y)
Regression
coefficient for
difference
between groups
(mm/y)
Standard
error
P
valuec
.798 2.74/2.87 0.13 0.21 .537
.009 3.37/2.74 0.63 0.24 .009
.504 2.80/2.80 0.00 0.18 .984
.391 2.65/2.83 0.18 0.20 .381
.174 1.92/2.81 0.90 0.55 .106
.489 2.91/2.76 0.16 0.14 .276
giotensin converting enzyme; IHD, ischemic heart disease.
PI, diabetes, history of hypertension and use of any antihypertensives, ACE
y.
multiple testing, the P value for judging statistical significance reduces to .009.erowth
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studies.2,11 The purpose of this investigation was to deter-
mine the effect of ACE inhibitors on aneurysm growth, but
we did evaluate the effects of other categories of the more
commonly used antihypertensive drugs none of which
showed marked effects on aneurysm growth. Similarly, the
use of any medication for hypertension did not have a
marked effect on aneurysm growth. The association be-
tween use of ACE inhibitors and increased aneurysm
growth remained of borderline significance even after al-
lowing for multiple testing.
Our study benefited from the prospective collection of
data by carefully trained trial coordinators.5 The data were
collected over 10 years ago, and although the same ACE
inhibitors (captopril, enalapril, lisinopril) are still being
used, newer ACE inhibitors such as ramipril or perindopril
would be more likely to be prescribed today. In addition,
the use of other drugs, particularly statins has escalated in
the last decade. Very few patients were using statins in this
study, but there was an indication that such patients had a
lower aneurysm growth rate, in keeping with a meta-
analysis of observational studies.2 However, more recently,
a larger observational study of the effect of statins on
aneurysm growth reported no evidence for an association
between statin use and lower aneurysm growth rates.12
Like all observational studies, our results are subject to bias
from confounding factors. We have adjusted our data for
known confounders of aneurysm growth, including diabe-
tes, blood pressure, ankle-brachial pressure index, and
smoking status, which previously have been identified as
associated with aneurysm growth in this and other co-
horts,7,8,13 but this did not diminish either the strength of
our findings or the size of the growth rate increase associ-
ated with use of ACE inhibitors. Patients using ACE inhib-
itors were more likely to have significant cardiac or coro-
nary artery disease at baseline, but again, adjustment for this
did not influence the results.
Our findings are discordant with another observational
study indicating that use of ACE inhibitors reduces the
likelihood of aneurysms presenting with rupture.3 The
ACE inhibitors used in Canada during the period of this
study, 1992 to 2002, were broadly similar to those used in
the UK, with use of ramipril not escalating until after
1999.14 However, in the Canadian study of aneurysm
rupture,3 there was no evidence for a dose-response rela-
tionship in protection against aneurysm rupture: lower
doses seemed more efficacious than higher doses of ACE
inhibitors and those who had discontinued ACE inhibitors,
3 to 12 months earlier, had a much increased risk of
presenting with rupture.15 It remains possible that ACE
inhibitors have contrasting effects on aneurysm growth and
rupture.
Many patients with AAAs have hypertension. ACE
inhibitors are used more widely today than they were 10 to20 years ago. Our observations underscore the urgent need
for a randomized trial of the effect of ACE inhibitors on
aneurysm growth rates to assess whether this class of drug
protects or harms the patient with an AAA.
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